Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study.
Adverse pregnancy outcomes
Cesarean section
Eclampsia
Fetal growth restriction
Hypertensive disorder of pregnancy
New ISSHP criteria
Nonreassuring fetal status
Preeclampsia
Pregnancy complications
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
06 Oct 2021
06 Oct 2021
Historique:
received:
15
01
2021
accepted:
23
09
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Preeclampsia (PE) is a hypertensive disorder specific to pregnancy that can cause severe maternal-neonatal complications. The International Society for the Study of Hypertension in Pregnancy revised the PE criteria in 2018; a PE diagnosis can be established in the absence of proteinuria when organ or uteroplacental dysfunction occurs. The initial findings of PE (IFsPE) at the first diagnosis can vary considerably across patients. However, the impacts of different IFsPE on patient prognoses have not been reported. Thus, we investigate the predictors of pregnancy complications and adverse pregnancy outcomes based on IFsPE according to the new criteria. This retrospective study included 3729 women who delivered at our hospital between 2015 and 2019. All women were reclassified based on the new PE criteria and divided into three groups based on the IFsPE: Classification 1 (C-1), proteinuria (classical criteria); Classification 2 (C-2), damage to other maternal organs; and Classification 3 (C-3), uteroplacental dysfunction. Pregnancy complications and adverse pregnancy outcomes were assessed and compared among the three groups. In total, 104 women with PE were included. Of those, 42 (40.4%), 28 (26.9%), and 34 (32.7%) were assigned to C-1, C-2, and C-3 groups, respectively. No significant differences in maternal characteristics were detected among the three groups, except for gestational age at PE diagnosis (C-1, 35.5 ± 3.0 weeks; C-2, 35.2 ± 3.6 weeks; C-3, 31.6 ± 4.6 weeks, p < 0.01). The rates of premature birth at < 37 weeks of gestation, fetal growth restriction (FGR), and neonatal acidosis were significantly higher in the C-3 group compared to the C-1 and C-2 groups. Additionally, the composite adverse pregnancy outcomes of the C-3 group compared with C-1 and C-2 represented a significantly higher number of patients. PE patients with uteroplacental dysfunction as IFsPE had the most unfavorable prognoses for premature birth, FGR, acidosis, and composite adverse pregnancy outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Preeclampsia (PE) is a hypertensive disorder specific to pregnancy that can cause severe maternal-neonatal complications. The International Society for the Study of Hypertension in Pregnancy revised the PE criteria in 2018; a PE diagnosis can be established in the absence of proteinuria when organ or uteroplacental dysfunction occurs. The initial findings of PE (IFsPE) at the first diagnosis can vary considerably across patients. However, the impacts of different IFsPE on patient prognoses have not been reported. Thus, we investigate the predictors of pregnancy complications and adverse pregnancy outcomes based on IFsPE according to the new criteria.
METHODS
METHODS
This retrospective study included 3729 women who delivered at our hospital between 2015 and 2019. All women were reclassified based on the new PE criteria and divided into three groups based on the IFsPE: Classification 1 (C-1), proteinuria (classical criteria); Classification 2 (C-2), damage to other maternal organs; and Classification 3 (C-3), uteroplacental dysfunction. Pregnancy complications and adverse pregnancy outcomes were assessed and compared among the three groups.
RESULTS
RESULTS
In total, 104 women with PE were included. Of those, 42 (40.4%), 28 (26.9%), and 34 (32.7%) were assigned to C-1, C-2, and C-3 groups, respectively. No significant differences in maternal characteristics were detected among the three groups, except for gestational age at PE diagnosis (C-1, 35.5 ± 3.0 weeks; C-2, 35.2 ± 3.6 weeks; C-3, 31.6 ± 4.6 weeks, p < 0.01). The rates of premature birth at < 37 weeks of gestation, fetal growth restriction (FGR), and neonatal acidosis were significantly higher in the C-3 group compared to the C-1 and C-2 groups. Additionally, the composite adverse pregnancy outcomes of the C-3 group compared with C-1 and C-2 represented a significantly higher number of patients.
CONCLUSIONS
CONCLUSIONS
PE patients with uteroplacental dysfunction as IFsPE had the most unfavorable prognoses for premature birth, FGR, acidosis, and composite adverse pregnancy outcomes.
Identifiants
pubmed: 34615491
doi: 10.1186/s12884-021-04152-2
pii: 10.1186/s12884-021-04152-2
pmc: PMC8495959
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
678Informations de copyright
© 2021. The Author(s).
Références
J Obstet Gynaecol Res. 2009 Oct;35(5):882-7
pubmed: 20149036
Sci Rep. 2015 Oct 16;5:15271
pubmed: 26471339
Growth Factors. 2010 Aug;28(4):293-8
pubmed: 20214506
Semin Perinatol. 2000 Feb;24(1):24-8
pubmed: 10709854
Am J Obstet Gynecol. 2021 Apr;224(4):398.e1-398.e11
pubmed: 32926859
J Obstet Gynaecol Res. 2017 Dec;43(12):1805-1814
pubmed: 28929598
Acta Obstet Gynecol Scand. 2014 Oct;93(10):959-64
pubmed: 25139038
Nat Rev Drug Discov. 2005 Mar;4(3):221-35
pubmed: 15738978
J Hypertens. 2010 Jul;28(7):1349-55
pubmed: 20467325
Am J Perinatol. 2018 Jul;35(8):785-790
pubmed: 29298455
Artif Organs. 2009 Feb;33(2):159-63
pubmed: 19178461
Placenta. 2009 Mar;30 Suppl A:S32-7
pubmed: 19070896
Hypertension. 2018 Jul;72(1):24-43
pubmed: 29899139
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
Am J Obstet Gynecol. 2007 Mar;196(3):237.e1-5
pubmed: 17346535
Front Immunol. 2020 Aug 18;11:1864
pubmed: 33013837
BMC Pregnancy Childbirth. 2019 May 9;19(1):163
pubmed: 31072315